Lymphodepleting Conditioning

Phase 1Small molecule

Lymphodepleting Conditioning is one of 40 small molecule programs targeting Autoimmune Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Blincyto

Amgen

Phase 2

1 5

Cytosar

Teva

Phase 2

1 6

Soliris

Rayos

2 8

Alkeran

AApotex Inc.

Phase 2

1 9

Velcade

SShilpa Grover, MD, MPH

Phase 2

1 10

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Autoimmune Disease

NCT07337785

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Recruiting·DDaishi Tian·Phase 1·NCT07337785·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lymphodepleting Conditioning. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lymphodepleting Conditioning compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lymphodepleting Conditioning. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daishi Tian company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDaishi Tian

Lymphodepleting Conditioning

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Autoimmune Disease1 trial

References

Drug Info

Quick Facts

Related News